Chemical drug research and development

Glorious Moment丨Haibu Pharmaceutical has received multiple honors!

Beijing Haibu Pharmaceutical Technology Co., Ltd. has been honored as one of the "Top 50 R&D Companies in the Pharmaceutical Industry for 2023-2024", marking another consecutive year for Haibu Pharmaceutical to receive this accolade.

【Announcement】Beijing Haibu Pharmaceutical Technology Co., Ltd. Hazardous Waste Pollution Prevention and Control Information Announcement

According to the requirements of the "Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste", units that generate solid waste shall timely disclose information on solid waste pollution to the environment in accordance with the law and actively accept social supervision.

【Good News】Haibu Pharmaceutical's Riluzole raw material has obtained the FDA registration number in the United States.

Our company has a wide variety of raw materials with stable supply. Welcome to inquire. Mr. Wei: 18515385101; Mr. Wu: 15600038801

【Good News】Haibu Pharmaceutical's Riluzole Tablets (40mg) have obtained clinical trial approval.

Introduction: The indications are to improve the following symptoms of uterine fibroids (excessive menstruation, lower abdominal pain, back pain, anemia); to alleviate the pain of endometriosis.

【Good News】Haibu Pharmaceutical's Isavuconazole Sulfate API has obtained the CDE registration number.

Haibu Pharmaceutical has a wide variety of raw materials, welcome to inquire.

【Good News】Haibu Pharmaceutical's pregabalin oral solution has obtained a production license.

Pregabalin oral solution has obtained production approval [National Drug Standard H20244981], used for the treatment of postherpetic neuralgia; fibromyalgia; and as an adjunctive treatment for partial seizures in adults.